Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Angi Inc (ANGI) vs Heron Therapeutics Inc (HRTX) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Angi Inc vs Heron Therapeutics Inc — how do they compare? Angi Inc trades at $4.34 (market cap $182.30M), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Angi Inc is far larger — about 3× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.

ANGIHRTX
Market Cap
$182.30M$61.47M
Sector
MediaHealth
52-Week High
$18.46$1.49
52-Week Low
$4.49$0.32
Enterprise Value
$392.07M$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Angi Inc

ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.

The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Angi Inc

Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair

Read more on ANGI

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX